Our research group focuses on integrating research into clinical practice in individuals of all ages with autism spectrum disorders (ASD), Fragile X Syndrome (FXS), and Angelman Syndrome (AS). The research team is composed of psychiatrists, neuroscientists, psychologists, speech pathologists, and research coordinators who are interested in improving the quality of life for individuals with developmental disorders.
Our lab is dedicated to understanding the causes and treatment of ASD. Learn more about our research.
As the leading expert in FXS, Craig Erickson, MD, has been investigating the use of acamprosate in individuals with Fragile X. Learn more about this research.
We are working to develop new targeted drug treatments in developmental disabilities. Learn more about our research.